New 2021 Forecasts Released

New Data
innovation hub

Mnemosyne Pharmaceuticals is Profiled in this Database

Updated At 30 Apr, 2012

Start Free 7 Day Trial Now
Partial description of this company
First-in-class subunit-selective NMDA receptor modulators to treat neuropsychiatric diseases, specifically schizophrenia and Alzheimer\'s

Start Trial Get Full Profile

There’s no risk. Start your trial today to see profiles of Mnemosyne Pharmaceuticals plus 4810 other startups.

Start Free 7 Day Trial Now

Learn More About Mnemosyne Pharmaceuticals

Technology/product details

Revenue projections

Capital raised to date

Growth strategy

More

Our Clients